Can This Beaten-Down Stock Bounce Back in 2025?
In 2022, pharmaceutical giant (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price. Pfizer has made progress, especially on the clinical and regulatory fronts, through acquisitions and internally developed programs. But nothing has stopped the bleeding -- yet.
Could 2025 be different? Let's see whether the drugmaker can finally turn things around this year.
Pfizer's woes started because it couldn't keep delivering the kinds of financial results it did during the earlier pandemic years, or even anything close to that. If the drugmaker can at least consistently grow its revenue and earnings at a good clip, that might lead more investors to buy the stock at current levels.
Source Fool.com
Pfizer Inc. Aktie
Positive Tendenz bei Pfizer Inc. mit mehreren Buy-Einschätzungen als Sell-Einschätzungen.
Ein Kursziel von 27 € für Pfizer Inc. könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 21.81 € führen.
